Ark Clinical Research | Long Beach, CA

Research site

(Unclaimed)

Location

2600 Redondo Avenue, Suite 400, Long Beach, California, United States of America

Site insights

Top conditions

Top treatments

Orforglipron

LY3502970

Ritonavir

Retatrutide

PF-07321332

Survodutide

Ruxolitinib

Brequinar

VXA-CoV2-1.1-S

Pimodivir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 46 total trials

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior...

Enrolling

Overweight or Obesity

OSA

Drug: Placebo

Drug: Orforglipron

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1) and in chil...

Active, not recruiting

Respiratory Syncytial Virus

Biological: Placebo

Biological: mRNA-1345

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in p...

Active, not recruiting

Type 2 Diabetes

Drug: Orforglipron

Drug: Dapagliflozin

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Placebo for Upadacitinib

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Locations recently updated

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (Nova 301)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling

Acute Gastroenteritis

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight

This study is open to adults who are at least 18 years old and have* presumed or confirmed NASH together with overweight or obesity and* a body mass...

Active, not recruiting

Non-Alcoholic SteatoHepatitis (NASH)

Obesity

Drug: Survodutide

Drug: Placebo

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ina...

Active, not recruiting

Diabetes Type 2

Drug: Placebo

Drug: Retatrutide

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The st...

Not yet enrolling

Obesity and Overweight

Drug: GZR18

Drug: Tirzepatide

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Drug: Survodutide

Drug: Placebo

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokine...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: BMF-219

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting

COVID-19

Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

Other: Placebo

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adu...

Active, not recruiting

Norovirus Acute Gastroenteritis

Biological: Placebo

Biological: mRNA-1403

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo